Asia Pacific Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Ana

Asia Pacific Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)

The Asia Pacific pharmacokinetics services market was valued at US$ 191.44 million in 2023 and is expected to reach US$ 356.58 million by 2031; it is estimated to register a CAGR of 8.1% from 2023 to 2031.

Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics Boost Asia Pacific Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the Asia Pacific pharmacokinetics services market in the near future.

Asia Pacific Pharmacokinetics Services Market Overview

The Asia Pacific pharmacokinetics services market growth in China is primarily attributed to the established pharmaceutical market, increasing R&D expenditures by pharmaceutical and biopharmaceutical companies, rising number of clinical trials due to lower operating costs, and favorable regulatory policies in place. According to the EFPIA report published in 2023, R&D expenditure by pharmaceutical companies in China grew from US$ 10,814.23 million in 2020 to US$ 12,989.23 million in 2021. China has the world's second-largest pharmaceutical market. The excessive population in the country, coupled with a rise in the cases of various noncommunicable and infectious diseases, fuels the need for new drug molecules, which makes China a prime market in Asia Pacific.

Asia Pacific Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Pharmacokinetics Services Market Segmentation

The Asia Pacific pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Asia Pacific pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Asia Pacific pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Asia Pacific pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Asia Pacific pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Asia Pacific pharmacokinetics services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific pharmacokinetics services market share in 2023.

Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; and Thermo Fisher Scientific Inc. are some of the leading companies operating in the Asia Pacific pharmacokinetics services market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pharmacokinetics services market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific pharmacokinetics services market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.